Biogen

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STAC, Gene, Orphan drug, ALTA, Haemophilia A, BBB, Patient, Health care, Quality of life, IND, Male, ERT, Investment, Therapy, Fabry disease, Plasma, Kite, Gene expression, Partnership, Central nervous system, Novartis, CNS, Pivotal, EMA, Prion, STAAR, Enzyme replacement therapy, Biogen, Tauopathy, Workforce, BLA, AAV, Sanofi, Research, DRG, Neuron, Hematology, FDA, DSM-IV codes, Brain, Sangamo Therapeutics, MAA, Haemophilia, CTA, Mouse, Female, Traffic barrier, Sodium, MHRA, Excipient, Society, Spinal cord, Toxicology, Sigma-Aldrich, Liver, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
  • “In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company,” said Sandy Macrae, Chief Executive Officer of Sangamo.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.
  • Revenues for the fourth quarter ended December 31, 2023 were $2.0 million, compared to $27.2 million for the same period in 2022.

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Retrieved on: 
Wednesday, March 13, 2024
Research, Neurology, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, STAC, AAV, Sangamo Therapeutics, Gene, Brain, Capsid, Gene expression, ALS, BBB, Central nervous system, Novartis, CNS, CTA, DRG, Traffic barrier, Prion, NHP, Tropism, IND, Nav1.7, Neuron, Biogen, Tauopathy, Excipient, Therapy, DSM-IV codes, Spinal cord, Liver, Animal, Vaccine

Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.

Key Points: 
  • Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.
  • In NHP studies when administered intravenously at clinically relevant doses, STAC-BBB demonstrated its potential to be a leading neurotropic capsid.
  • Exhibited 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published neurotropic capsid variants evaluated in the study.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Retrieved on: 
Monday, March 11, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, BIIB, SVP, Brain, Doctor of Philosophy, Biogen, Antibody, Neuroscience, ABCL

AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.

Key Points: 
  • AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
  • “Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera.
  • “We are excited to work with Biogen on this innovative program, which has the potential to unlock multiple new approaches to treating neurological conditions.”
    Under the terms of the agreement, AbCellera will receive an upfront payment and is eligible to receive additional milestone payments should the research programs achieve certain research, developmental and regulatory milestones.
  • AbCellera is also eligible to receive potential royalties on future net sales of products that result from the collaboration.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Tuesday, March 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Tuesday, March 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth

Retrieved on: 
Monday, March 11, 2024
Gilead Sciences, Chemistry, Mantra, Sale, IPO, Doctor of Philosophy, University, Therapy, Business, Organization, Novartis, Bachelor of Science, Science, Biogen, Management

LEXINGTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Hyku Biosciences, Inc. (Hyku), a covalent precision medicine company, today announced the appointment of Kleem Chaudhary, Ph.D. as President and Chief Executive Officer, succeeding co-founder and acting CEO Milind Deshpande, Ph.D. who will now serve as an advisor to the company. Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.

Key Points: 
  • Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.
  • Most recently, he was Chief Operating and Business Officer at Redona Therapeutics.
  • Dr. Chaudhary holds a Ph.D. in chemistry from the University of North Carolina at Chapel Hill and a B.Sc.
  • “We are excited to have Kleem join Hyku and I look forward to working with him to advance the exciting science at Hyku.”

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

Retrieved on: 
Thursday, March 7, 2024
Biogen, Prior, LLP, News, Pomerantz, Cryptocurrency

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB).
  • The investigation concerns whether Biogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Retrieved on: 
Wednesday, March 6, 2024
ALS, Aes, Research, RESPOND, BIIB, SMN2, Spinal muscular atrophy, Conference, Biogen, SMA, Safety, Biomarker, AFL, Patient, MDA, Development, Episcopal conference, Birth control

* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec).

Key Points: 
  • * The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec).
  • The new data show that plasma neurofilament light chain (NfL) levels, an objective biomarker of axonal injury and neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA.
  • These data will be presented at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 3-6, 2024).
  • “Our evolving understanding of gene therapy indicates there may be an opportunity for better outcomes,” said Crystal Proud, M.D., Pediatric Neurologist at Children’s Hospital of the King’s Daughters.

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024
OGA, Research, BIIB, Investment, Eisai, Alpha-synuclein, Amyloid, Conference, Biogen, Quantitative systems pharmacology, Dementia, MCI, QSP, Clarity, MAPT, Brain, Vaccine

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study

Retrieved on: 
Wednesday, February 28, 2024
Eli Lilly, African Americans, Merck, IXICO, Person, Research, Collaborative writing, Blood, AbbVie, Diagnosis, Volunteering, Digital technology, Roche, University, Biomarker, GAP, Journal, Disease, Alzheimer's Drug Discovery Foundation, White Americans, Brain, Amyloid plaques, PET, Biogen, Medical imaging

These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.

Key Points: 
  • These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.
  • GAP is proud that we succeeded in ensuring that the participants in this study reflected the diverse underrepresented populations afflicted with dementia.
  • With the recent approval of disease-modifying Alzheimer’s treatments, there is a growing need to simplify and accelerate an accurate diagnosis.
  • Dr. Richard Mohs observed that “This paper moves the field ahead in simplifying the diagnosis of Alzheimer’s disease.